Covering the whole value chain of pharmaceutical R&DVectorB2B is your partner for cost-efficient, rapid, and tailored-made solutions every-step-of-the-way in drug discovery & development
Seamless process development from lab to GMPOur specialists develop the best process for your needs, including galenic formulation and biologic cultures – from lab scale to bioreactor.
Accelerate SARS-CoV-2 therapeutic, vaccine or test developmentLet us support you in the fight against COVID-19 with our antibody development services and our clinical trial expertise.
Driving force in drug development
Portugal’s best teams in science and clinics have joined forces to provide cutting-edge, customized solutions in drug development for academia and industry
Hear from our Clients
SVP Research, Atreca, Inc.
“Working with Vector B2B not only provided us with great data and thorough reports regarding the experiments we requested, but their scientific expertise helped optimize and improve the design of our experiments and success of our project. I definitely recommend engaging VectorB2B
“AFFIX Labs is a fast moving chemical technology company that is in need of partners that can keep up with our needs. VectorB2B has proven to be a flexible partner that is willing to go beyond the expected service level. During the start of the Corona pandemic VectorB2B was able to support our company in proving that our anti-viral coating was effective against the pathogen that causes COVID-19, they were able to overcome challenges in an excellent manner and kept up with proper communications doing so.
We expect to work on more projects in the near future”.
CEO AFFIX Labs
Tell us how we can help you
Applying CellectAB technology to generate antibodies against CD3
Alginate Hydrogels for Medical Applications
Developing a xenograft mouse model of canine diffuse large B-cell lymphoma (DLBCL)
Process Development of Bacteriophages for application in Diagnostic Kits for the Food Industry
Assay development for the evaluationof antiviral COVID-19 surface coatings
Investigating the potential of new therapeutic strategies relevant for the treatment of glaucoma
news & announcements
We are very pleased to announce that our Head of CMC, Teresa Duarte, will be a special guest of Cellexus joining the Phage Futures Congress. Teresa will
We are very pleased to be attending the Infectious Diseases Virtual Partnering from 2-4 December, 2020. If you have any questions, please contact our specialist. Vector B2B
Drug Developing – Associação para Investigação em Biotecnologia
Avenida Professor Gama Pinto nº.2
Alameda da Universidade,